Literature DB >> 6378259

No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.

F Lotstra, P Verbanck, J Mendlewicz, J J Vanderhaeghen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6378259

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  9 in total

1.  Effect of ceruletide on tardive dyskinesia: a pilot study of quantitative computer analyses on electromyogram and microvibration.

Authors:  T Nishikawa; M Tanaka; A Tsuda; H Kuwahara; I Koga; Y Uchida
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.

Authors:  F Weiss; A Ettenberg; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.

Authors:  C A Tamminga; R L Littman; L D Alphs; T N Chase; G K Thaker; A M Wagman
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Cyclic cholecystokinin analogues with high selectivity for central receptors.

Authors:  B Charpentier; D Pelaprat; C Durieux; A Dor; M Reibaud; J C Blanchard; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.

Authors:  E Peselow; B Angrist; A Sudilovsky; J Corwin; J Siekierski; F Trent; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 6.  Neuropeptides: animal behaviour and human psychopathology.

Authors:  D de Wied; J M van Ree
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

7.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

8.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

9.  A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin.

Authors:  R Pietrowsky; A Thiemann; W Kern; H L Fehm; J Born
Journal:  Psychoneuroendocrinology       Date:  1996-08       Impact factor: 4.905
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.